Drug intelligence / Profile preview

AD-227

Development stage: Phase 1
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

**AD-227** is an investigational oral fixed-dose combination tablet developed by Addpharma for primary hypertension. It contains the active components represented in public trial records as AD-227A and AD-227B and is being evaluated against co-administration of one tablet each of those two component products to characterize comparative pharmacokinetics and safety. The identities and molecular targets of AD-227A and AD-227B have not been publicly disclosed in the identified trial records.

Targets

LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on AD-227.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-227.

Explore the full profile